Evolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,236 Shares

Evolus, Inc. (NASDAQ:EOLS) insider David Moatazedi sold 6,236 shares of Evolus stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $13.86, for a total value of $86,430.96. Following the completion of the sale, the insider now directly owns 689,614 shares of the company’s stock, valued at approximately $9,558,050.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

David Moatazedi also recently made the following trade(s):

• On Thursday, February 22nd, David Moatazedi sold 7,706 shares of Evolus stock. The stock was sold at an average price of $13.08, for a total value of $100,794.48.

Evolus Stock Performance

NASDAQ:EOLS remained flat at $14.00 during mid-day trading on Friday. The company’s stock had a trading volume of 706,671 shares, compared to its average volume of 739,170. The company has a 50 day moving average of $13.60 and a two-hundred day moving average of $10.78. Evolus, Inc. has a twelve month low of $7.07 and a twelve month high of $15.43. The company has a market cap of $811.16 million, a price-to-earnings ratio of -12.84 and a beta of 1.45.

Analyst Upgrades and Downgrades

Several analysts recently commented on EOLS shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Evolus in a report on Wednesday, December 20th. Barclays raised Evolus from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $10.00 to $16.00 in a report on Monday, January 29th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Evolus in a report on Friday, March 1st.

Institutional Trading of Evolus

Several hedge funds have recently bought and sold shares of EOLS. JPMorgan Chase & Co. grew its holdings in Evolus by 30.4% during the first quarter. JPMorgan Chase & Co. now owns 22,312 shares of the company’s stock valued at $251,000 after purchasing an additional 5,199 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Evolus by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 107,026 shares of the company’s stock worth $1,202,000 after acquiring an additional 1,472 shares during the period. MetLife Investment Management LLC bought a new position in shares of Evolus in the first quarter worth about $220,000. Metropolitan Life Insurance Co NY bought a new position in shares of Evolus in the first quarter worth about $26,000. Finally, Panagora Asset Management Inc. bought a new position in shares of Evolus in the first quarter worth about $555,000. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.